

BEST AVAILABLE COPY

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
14 June 2001 (14.06.2001)

PCT

(10) International Publication Number
WO 01/42288 A2

(51) International Patent Classification: C07K 14/00

(21) International Application Number: PCT/US00/33382

(22) International Filing Date: 7 December 2000 (07.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/172,852 10 December 1999 (10.12.1999) US
60/171,732 22 December 1999 (22.12.1999) US
60/176,148 14 January 2000 (14.01.2000) US
60/177,331 21 January 2000 (21.01.2000) US

(71) Applicant (for all designated States except US): INCYTE GENOMICS, INC. [US/US]; 3160 Porter Drive, Palo Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BURFORD, Neil [GB/US]; 105 Wildwood Circle, Durham, CT 06422 (US).

BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). AU-YOUNG, Janice [US/US]; 233 Golden Eagle Lane, Brisbane, CA 94005 (US). YANG, Junming [CN/US]; 7125 Bark Lane, San Jose, CA 95129 (US). LU, Dyung, Alina, M. [US/US]; 233 Coy Drive, San Jose, CA 95123 (US). REDDY, Roopa [IN/US]; 1233 W. McKinley Avenue #3, Sunnyvale, CA 94086 (US).


(74) Agents: HAMLET-COX, Diana et al.; Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian

[Continued on next page]

(54) Title: G-PROTEIN COUPLED RECEPTORS



(57) Abstract: The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating a disease associated with aberrant expression of GCREC.

WO 01/42288 A2



patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— Without international search report and to be republished upon receipt of that report.

What is claimed is:

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
 - 5 a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-39,
 - b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-39,
 - c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-39, and
 - 10 d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-39.
2. An isolated polypeptide of claim 1 selected from the group consisting of SEQ ID NO:1-39.
- 15 3. An isolated polynucleotide encoding a polypeptide of claim 1.
4. An isolated polynucleotide encoding a polypeptide of claim 2.
- 20 5. An isolated polynucleotide of claim 4 selected from the group consisting of SEQ ID NO:40-78.
6. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.
- 25 7. A cell transformed with a recombinant polynucleotide of claim 6.
8. A transgenic organism comprising a recombinant polynucleotide of claim 6.
- 30 9. A method for producing a polypeptide of claim 1, the method comprising:
 - a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and
 - 35 b) recovering the polypeptide so expressed.

10. An isolated antibody which specifically binds to a polypeptide of claim 1.

11. An isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of:

- 5 a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:40-78,
- b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:40-78,
- c) a polynucleotide sequence complementary to a),
- d) a polynucleotide sequence complementary to b), and
- 10 e) an RNA equivalent of a)-d).

12. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 11.

15 13. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:

- a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization
- 20 complex is formed between said probe and said target polynucleotide or fragments thereof, and
- b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

25 14. A method of claim 13, wherein the probe comprises at least 60 contiguous nucleotides.

15. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:

- a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and
- 30 b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

16. A composition comprising an effective amount of a polypeptide of claim 1 and a pharmaceutically acceptable excipient.

17. A composition of claim 16, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-39.

18. A method for treating a disease or condition associated with decreased expression of functional GCREC, comprising administering to a patient in need of such treatment the composition of claim 16.

19. A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting agonist activity in the sample.

20. A composition comprising an agonist compound identified by a method of claim 19 and a pharmaceutically acceptable excipient.

21. A method for treating a disease or condition associated with decreased expression of functional GCREC, comprising administering to a patient in need of such treatment a composition of claim 20.

22. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting antagonist activity in the sample.

23. A composition comprising an antagonist compound identified by a method of claim 22 and a pharmaceutically acceptable excipient.

24. A method for treating a disease or condition associated with overexpression of functional GCREC, comprising administering to a patient in need of such treatment a composition of claim 23.

25. A method of screening for a compound that specifically binds to the polypeptide of claim 1, said method comprising the steps of:

- a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and
- b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a

compound that specifically binds to the polypeptide of claim 1.

26. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, said method comprising:

- 5 a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1,
- b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and
- c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in
- 10 the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.

27. A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method

15 comprising:

- a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,
- b) detecting altered expression of the target polynucleotide, and
- c) comparing the expression of the target polynucleotide in the presence of varying amounts of
- 20 the compound and in the absence of the compound.

28. A method for assessing toxicity of a test compound, said method comprising:

- a) treating a biological sample containing nucleic acids with the test compound;
- b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at
- 25 least 20 contiguous nucleotides of a polynucleotide of claim 11 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 11 or fragment thereof;
- c) quantifying the amount of hybridization complex; and
- 30 d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

Gly Lys Phe Val	260	Leu Phe Tyr Thr	265	Val Val Thr Pro Ala	270
	275		280		285
Asn Pro Leu Ile	290	Tyr Thr Leu Arg Asn	295	Lys Val Lys Gly	300
Ala Arg Arg Leu	305	Leu Arg Ser Leu Gly	310	Arg Gly Gln Ala Gly	315

<210> 23
 <211> 470
 <212> PRT
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 3275821CD1

<400> 23

Met Asp Thr Thr	Met Glu Ala Asp	Leu Gly Ala Thr	Gly His Arg
1	5	10	15
Pro Arg Thr Glu	Leu Asp Asp Glu	Asp Ser Tyr Pro	Gln Gly Gly
	20	25	30
Trp Asp Thr Val	Phe Leu Val Ala	Leu Leu Leu Gly	Leu Pro
	35	40	45
Ala Asn Gly Leu	Met Ala Trp Leu	Ala Gly Ser Gln	Ala Arg His
	50	55	60
Gly Ala Gly Thr	Arg Leu Ala Leu	Leu Leu Ser Leu	Ala Leu
	65	70	75
Ser Asp Phe Leu	Phe Leu Ala Ala	Ala Phe Gln Ile	Leu Glu
	80	85	90
Ile Arg His Gly	Gly His Trp Pro	Leu Gly Thr Ala	Ala Cys Arg
	95	100	105
Phe Tyr Tyr Phe	Leu Trp Gly Val	Ser Tyr Ser Ser	Gly Leu Phe
	110	115	120
Leu Leu Ala Ala	Leu Ser Leu Asp	Arg Cys Leu Leu	Ala Leu Cys
	125	130	135
Pro His Trp Tyr	Pro Gly His Arg	Pro Val Arg Leu	Pro Leu Trp
	140	145	150
Val Cys Ala Gly	Val Trp Val Leu	Ala Thr Leu Phe	Ser Val Pro
	155	160	165
Trp Leu Val Phe	Pro Glu Ala Ala	Val Trp Trp Tyr	Asp Leu Val
	170	175	180
Ile Cys Leu Asp	Phe Trp Asp Ser	Glu Glu Leu Ser	Leu Arg Met
	185	190	195
Leu Glu Val Leu	Gly Phe Leu Pro	Phe Leu Leu Leu	Leu Val
	200	205	210
Cys His Val Leu	Thr Gln Ala Thr	Ala Cys Arg Thr	Cys His Arg
	215	220	225
Gln Gln Gln Pro	Ala Ala Cys Arg	Gly Phe Ala Arg	Val Ala Arg
	230	235	240
Thr Ile Leu Ser	Ala Tyr Val Val	Leu Arg Leu Pro	Tyr Gln Leu
	245	250	255
Ala Gln Leu Leu	Tyr Leu Ala Phe	Leu Trp Asp Val	Tyr Ser Gly
	260	265	270
Tyr Leu Leu Trp	Glu Ala Leu Val	Tyr Ser Asp Tyr	Leu Ile Leu
	275	280	285
Leu Asn Ser Cys	Leu Ser Pro Phe	Leu Cys Leu Met	Ala Ser Ala
	290	295	300
Asp Leu Arg Thr	Leu Leu Arg Ser	Val Leu Ser Ser	Phe Ala Ala
	305	310	315
Ala Leu Cys Glu	Glu Arg Pro Gly	Ser Phe Thr Pro	Thr Glu Pro
	320	325	330
Gln Thr Gln Leu	Asp Ser Glu Gly	Pro Thr Leu Pro	Glu Pro Met
	335	340	345
Ala Glu Ala Gln	Ser Gln Met Asp	Pro Val Ala Gln	Pro Gln Val
	350	355	360

Asn	Pro	Thr	Leu	Gln	Pro	Arg	Ser	Asp	Pro	Thr	Ala	Gln	Pro	Gln
				365					370					375
Leu	Asn	Pro	Thr	Ala	Gln	Pro	Gln	Ser	Asp	Pro	Thr	Ala	Gln	Pro
				380					385					390
Gln	Leu	Asn	Leu	Met	Ala	Gln	Pro	Gln	Ser	Asp	Ser	Val	Ala	Gln
				395					400					405
Pro	Gln	Ala	Asp	Thr	Asn	Val	Gln	Thr	Pro	Ala	Pro	Ala	Ala	Ser
				410					415					420
Ser	Val	Pro	Ser	Pro	Cys	Asp	Glu	Ala	Ser	Pro	Thr	Pro	Ser	Ser
				425					430					435
His	Pro	Thr	Pro	Gly	Ala	Leu	Glu	Asp	Pro	Ala	Thr	Pro	Pro	Ala
				440					445					450
Ser	Glu	Gly	Glu	Ser	Pro	Ser	Ser	Thr	Pro	Pro	Glu	Ala	Ala	Pro
				455					460					465
Gly	Ala	Gly	Pro	Thr										
				470										

<210> 24

<211> 358

<212> PRT

<213> Homo sapiens

<220>

<221> misc_feature

<223> Incyte ID No: 3744167CD1

<400> 24

Met	Ser	Val	Cys	Tyr	Arg	Pro	Pro	Gly	Asn	Glu	Thr	Leu	Leu	Ser
1				5					10					15
Trp	Lys	Thr	Ser	Arg	Ala	Thr	Gly	Thr	Ala	Phe	Leu	Leu	Leu	Ala
				20					25					30
Ala	Leu	Leu	Gly	Leu	Pro	Gly	Asn	Gly	Phe	Val	Val	Trp	Ser	Leu
				35					40					45
Ala	Gly	Trp	Arg	Pro	Ala	Arg	Gly	Arg	Pro	Leu	Ala	Ala	Thr	Leu
				50					55					60
Val	Leu	His	Leu	Ala	Leu	Ala	Asp	Gly	Ala	Val	Leu	Leu	Leu	Thr
				65					70					75
Pro	Leu	Phe	Val	Ala	Phe	Leu	Thr	Arg	Gln	Ala	Trp	Pro	Leu	Gly
				80					85					90
Gln	Ala	Gly	Cys	Lys	Ala	Val	Tyr	Tyr	Val	Cys	Ala	Leu	Ser	Met
				95					100					105
Tyr	Ala	Ser	Val	Leu	Leu	Thr	Gly	Leu	Leu	Ser	Leu	Gln	Arg	Cys
				110					115					120
Leu	Ala	Val	Thr	Arg	Pro	Phe	Leu	Ala	Pro	Arg	Leu	Arg	Ser	Pro
				125					130					135
Ala	Leu	Ala	Arg	Arg	Leu	Leu	Leu	Ala	Val	Trp	Leu	Ala	Ala	Leu
				140					145					150
Leu	Leu	Ala	Val	Pro	Ala	Ala	Val	Tyr	Arg	His	Leu	Trp	Arg	Asp
				155					160					165
Arg	Val	Cys	Gln	Leu	Cys	His	Pro	Ser	Pro	Val	His	Ala	Ala	Ala
				170					175					180
His	Leu	Ser	Leu	Glu	Thr	Leu	Thr	Ala	Phe	Val	Leu	Pro	Phe	Gly
				185					190					195
Leu	Met	Leu	Gly	Cys	Tyr	Ser	Val	Thr	Leu	Ala	Arg	Leu	Arg	Gly
				200					205					210
Ala	Arg	Trp	Gly	Ser	Gly	Arg	His	Gly	Ala	Arg	Val	Gly	Arg	Leu
				215					220					225
Val	Ser	Ala	Ile	Val	Leu	Ala	Phe	Gly	Leu	Leu	Trp	Ala	Pro	Tyr
				230					235					240
His	Ala	Val	Asn	Leu	Leu	Gln	Ala	Val	Ala	Ala	Leu	Ala	Pro	Pro
				245					250					255
Glu	Gly	Ala	Leu	Ala	Lys	Leu	Gly	Gly	Ala	Gly	Gln	Ala	Ala	Arg
				260					265					270
Ala	Gly	Thr	Thr	Ala	Leu	Ala	Phe	Phe	Ser	Ser	Ser	Val	Asn	Pro
				275					280					285
Val	Leu	Tyr	Val	Phe	Thr	Ala	Gly	Asp	Leu	Leu	Pro	Arg	Ala	Gly
				290					295					300


```
gctgtccctg tccctgtcca tgtatctggt caccgtgctg aggaacctgt tcagcatcct 240
ggctgtcagc tctgactgcc cctccacac ccccatgtac ttcttctctt ccaacctgtg 300
ctggcctgac atcggtttca cctcggccat gggtcccaag atgattgtgg acacgcagtc 360
gcatagcaga gtcactcttc atgctggctg cctgacacag atgtctttcc tgctccttgt 420
tgcatgtata gaaggcatgc tctgactgt gactgctttg tagccatctg 480
tcgcccctctg cactaccag tcactcgtgaa tcttcacctc tgtgtctttt tcgttttggg 540
gtcccttttct cttagcctgt tggattccca gctgcacagt tggattgtgt tacaataaac 600
catcatcaag aatgtggaaa tctctaattt ggtctgtgac cctctcaac ttctcaatct 660
tgctgtttct gacagcgtca tcaataacat attcataat ttcgatagta ctatgtttgg 720
ttttcttccc atttcaggga tctttttgtc ttactataaa attgtcccct ccattctaag 780
gatttcacgc tcagatggga agtataaagc cttctccacc tgtggctgtc atctagcagt 840
tggttgctgg ttttatggaa caggcattgg catgtacctg acttcagctg tgtaccacc 900
ccccaggaat ggtgtgggtg catcagtgat gtacgtgtg gtcaccccat gctgaacctt 960
tccatgtgca caggtgagaa cagggacata caaagtgcct tgccgaggct ggcagcaga 1020
gcattcgaat ctcatgatct gttccatcct ttttcttgtg tgggtgagaa agggcaatca 1080
cattaaatct ctttatctgc aaaaaaaaaa 1110
```

<210> 61
<211> 1095
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 2200534CB1

```
<400> 61
atgaaggcca actacagcgc agaggagcgc tttctcctgc tgggtttctc cgactgggct 60
tccctgcagc cggctcctctt cgcctctgtc ctctgtgctt accctctgac cttgacgggc 120
aactcggcgc tgggtctgctt ggcgggtgcgc gaccgcgcgc tgcacacgcc catgtactac 180
ttcctctgcc acctggcctt ggttagacgcg ggcttcaacta ctagcgtggg gccgccgctg 240
ctggccaacc tgcgcggacc agcgtctctgg ctgcccgcga gccactgcac ggccagctg 300
tgcccatcgc tggctctggg ttccggcgaa tgcgtctccc tggcgggtgat ggtcttgga 360
cgccgcggcg cagtgtgccc cccgctgcgc tatcgggggc tcgtctcccc gcgcctatgt 420
cgccagctgg ccagcgcctc ctggctaagc ggctcacca actcgggtgc gcaaaccgag 480
ctcctggctg aqcgccgctt gtcgcgcgcc cgcctgctgg accacttcat ctgtgagctg 540
ccggcgttgc tcaagctggc ctgcccaggc gacggagaca ctaccgagaa ccagatgttc 600
gccgcccgcg tggctcatct gctgtgccc catcggttca tcttgccctc ctacggctgc 660
gtggcccagc ctgtctgttg catgcccgtt agcggaggcc ggaggaggcc ggtgggcacg 720
tgtgggtccc acctgacagc cgtctgcctg ttctacggct cggccatcta cactacctg 780
cagcccgcgc agcgtctaaa ccaggcacgg ggcaagtctg tatcgtctt ctacaccgtg 840
gtcacacctg ctctcaacct gtcactctac accctcagga ataagaaagt gaagggggca 900
gcgaggaggc tgcctgcggg tctggggaga ggccaggctg ggcagtgagt agttggggag 960
gggagaaagt attagccag aacccaagga tggaaatacc ccttagtgag tcagttaga 1020
cttcaggctg ttcattttgc tatgataatc tgcaagattt gtccaaagga gtccaatggg 1080
ggatatgttt tctc 1095
```

<210> 62
<211> 1665
<212> DNA
<213> Homo sapiens

<220>
<221> misc_feature
<223> Incyte ID No: 3275821CB1

```
<400> 62
ttcctacctt cactgattct ctgaaccttc ctgtcctcgc ctgtaaagta gattgtatga 60
ggactccatg aggtcatcca cttcaagtcc ttggcatagg ataattactc aaaaggtgat 120
gacaatggcg cagggaggga tgggtgacttg cctggagatg cacagcaccg tctctcccat 180
actcggctcat tcacaccatc attgattcac caggcaccca ctccgtgtcc agcaggactc 240
tgggggacccc aaatggacac taccatggaa gctgacctgg gtgccactgg ccacaggccc 300
cgccacagagc ttgatgatga ggaactcctac cccaagggtg gctgggacac ggtcttctctg 360
gtggccctgc tgcctccttg gctgccagcc aatgggttga tggcgtggct ggccggctcc 420
cagggcccgc atggagctgg cacgcgtctg gcgctgctcc tgcctagcct ggccctctct 480
gacttcttgt tctggcagc agcggccttc cagatcctag agatccggca tgggggacac 540
tgcccgctgg ggacagctgc ctgccgcttc tactacttcc tatggggcgt gtccctactcc 600
```

tccggcctct	tccgtctggc	cgccctcagc	ctcgaccgct	gcctgtctggc	gctgtgccc	660
cactgggtacc	ctggggcaccg	cccagtcgcg	ctgccccctct	gggtctgcgc	cggtgtctgg	720
gtgtctggcca	cactcttcag	cgtgcccctgg	ctggtcttcc	ccgaggctgc	cgtctggtgg	780
tacgacctgg	tcatctgcct	ggacttctgg	gacagcgagg	agctgtctgct	gaggatgctg	840
gaggctctgg	ggggcttcc	gcctttccct	ctgctgctcg	tctgccacgt	gctcaccag	900
gccacagcct	gtcgcacctg	ccaccgccaa	cagcagccc	cagcctgccc	gggcttcgcc	960
cgtgtggcca	ggaccattct	gtcagcctat	gtggctctga	ggctgcccct	ccagctggcc	1020
cagctgctct	acctggccct	cctgtggggac	gtctactctg	gctacctgct	ctgggaggcc	1080
ctggtctact	ccgactacct	gatcctactc	aacagctgcc	tcagcccctt	cctctgcctc	1140
atggccagtg	ccgacctccg	gaccctgctg	cgtctcgtgc	tctcgtcctt	cgccggcagct	1200
ctctgcgagg	agcggccggg	cagcttcacg	cccactgagc	cacagaccct	gctagattct	1260
gagggtccaa	ctctgccaga	gccgatggca	gaggccagct	cacagatgga	tcctgtggcc	1320
cagcctcagg	tgaacccccc	actccagcca	cgatcggatc	ccacagctca	gccacagctg	1380
aacctacagg	ccagccaca	gtcggatccc	acagcccagc	cacagctgaa	cctcctggcc	1440
cagccacagt	cagattctgt	ggcccagcca	caggcagaca	ctaactgcca	gacccctgca	1500
cctgtctgcca	gtctgtgtgc	cagtcctctg	ctaggaagct	ccccaacccc	atcctcgcat	1560
cctaccgccag	gggcccctga	ggaccagccc	acactctctg	cctctgaagg	agaaagcccc	1620
agcagcacc	cgccagaggc	ggccccgggc	gcaggcccca	cgtga		1665

<210> 63
 <211> 1609
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 3744167CB1

<400> 63	tctccttttg	ccgattagtg	gacgtgacag	agatgtgaat	ggggcaggga	tgtcctttga	60
tggtcatcaag	actttagctt	ctgggtgcgct	gtgtcccagc	tctgatttca	gttgacggcc	120	
tgatggacag	ttgcatggaa	gctgagactc	tcactgacag	tgaacccctc	aaatgaacac	180	
aatccctgct	ttcctgccaa	ggatccttgt	agggctcccc	agcttcccca	ctttttttct	240	
gtgtcctgta	ggcccagaag	gatgtcggtc	tgctaccgtc	ccccaggga	cgagacactg	300	
ctgagctgga	agacttcgcg	ggccacaggc	acagccttcc	tgctgtctggc	ggcgtgctg	360	
gggtcctctg	gcaacgggct	cgtgggtgtg	agcttggcgg	gctggcggcc	tgacggggg	420	
cgaccgctgg	cggccacgct	tgtgtctgac	ctggcgctgg	ccgacggcgc	ggtgtgctg	480	
ctcacgcgcg	tctttgtggc	ottcctgacc	cggcaggcct	ggccgctggg	ccaggcgggc	540	
tgcaaggcgg	gttactacgt	gtgcgcgctc	agcatgtacg	ccagcgtgct	gctcacgggc	600	
ctgtctagcc	tgcaagcgtg	cctcgcagtc	acccgcccct	tcctggcgcc	tcggctgctg	660	
agcccggccc	tgggcccgcc	cctgtctgct	gcggtctggc	tgcccgccct	gttgcctgcc	720	
gtcccggccg	ccgtctaccg	ccacctgtgg	agggaccgcg	tatgccagct	gtgccaccgc	780	
tcgcccgttc	acgcccgcgc	ccacctgagc	ctggagactc	tgaccgcttt	cgtgcttctt	840	
ttcgggctga	tgctcggctg	ctacagcgtg	acgctggcac	ggctgcgggg	cgcccgctgg	900	
ggctccgggc	ggcacggggc	gcgggtgggc	cggtgtgtga	gcgccatcgt	gcttgccctc	960	
ggcttgcctc	gggcccccta	ccacgcagtc	aaacctctgc	agggcggtcg	agcgttggct	1020	
ccaccggaaq	gggccttggc	gaagctgggc	ggagccggcc	agggcggcgc	agcgggaact	1080	
acggccttgg	ccttcttcag	ttctagcgtc	aaaccgggtg	tctacgtctt	caccgctgga	1140	
gatctgtctg	cccgggcagg	tcccctgttc	ctcacgcggc	tcttcgaagg	ctctggggag	1200	
gcccaggggg	gcggccgctc	taggggaagg	accatggagc	tccgaactac	ccctcagctg	1260	
aaagtgggtg	ggcagggccg	cggcaatgga	gaccgggggg	gtgggatgga	gaaggacggg	1320	
ccggaatggg	acctttgaca	gcagacccta	caacctgctg	cccttccctg	tccctttcca	1380	
ccccccaccc	accttccaga	ggtcagtggt	ctgggacatt	tggggaccct	tctttgacta	1440	
gagtttggat	ctggctgggt	aggattacta	tacacttggg	gcaggcccag	gctcctccaa	1500	
actgagggat	tatgaggggt	gtgatgggtc	ctgttaaggga	ctattgtgtg	cttgcaagtt	1560	
ggcatgtacc	catgtgccag	caattgcttac	ttgttgccaa	tagctgtta		1609	

<210> 64
 <211> 945
 <212> DNA
 <213> Homo sapiens

<220>
 <221> misc_feature
 <223> Incyte ID No: 7472007CB1

<400> 64